Document is current
Any future updates will be listed below
-
Authors
Bond, Simon T. https://orcid.org/0000-0003-1551-8614
King, Emily J. https://orcid.org/0000-0002-4950-5662
Walker, Shannen M. https://orcid.org/0000-0001-5635-9184
Yang, Christine
Liu, Yingying
Liu, Kevin H.
Zhuang, Aowen
Jurrjens, Aaron W. https://orcid.org/0000-0003-2349-4122
Fang, Haoyun A.
Formosa, Luke E. https://orcid.org/0000-0002-7740-6151
Nath, Artika P.
Carmona, Sergio Ruiz https://orcid.org/0000-0003-4920-5915
Inouye, Michael
Duong, Thy https://orcid.org/0000-0002-2521-078X
Huynh, Kevin https://orcid.org/0000-0001-6170-2207
Meikle, Peter J. https://orcid.org/0000-0002-2593-4665
Crawford, Simon
Ramm, Georg https://orcid.org/0000-0003-3596-2288
Elahee Doomun, Sheik Nadeem https://orcid.org/0000-0002-6384-859X
de Souza, David P.
Rudler, Danielle L.
Calkin, Anna C. https://orcid.org/0000-0002-9861-0602
Filipovska, Aleksandra https://orcid.org/0000-0002-6998-8403
Greening, David W. https://orcid.org/0000-0001-7516-485X
Henstridge, Darren C. https://orcid.org/0000-0003-4988-767X
Drew, Brian G. https://orcid.org/0000-0002-7839-9467
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (2016530)
National Heart Foundation of Australia (101789)
- License Information
-
More Information
Article History
Received: 23 June 2024
Accepted: 13 February 2025
First Online: 8 March 2025
Competing interests
: BGD, STB and DCH together with the Baker Heart & Diabetes Institute declare they are pursuing protection of intellectual property (IP) around the use of proprietary folate cycle metabolite derivatives as therapeutics for mitochondrial diseases, and other degenerative conditions in which 1C-metabolism and the ISR are perturbed. All other authors declare no conflict of interest.
